No definition available.
Drug-induced interstitial lung disorders, unspecified
DRUGADVERS_INTERSTITIAL_LUNG_DISORD_UNSPE
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
69 |
4. Check minimum number of eventsNone |
69 |
5. Include endpointsNone |
69 |
6. Filter based on genotype QC (FinnGen only) |
67 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Drug-induced interstitial lung disorders, unspecified
based on the number of shared cases.
Similar with more cases:
- Respiratory conditions due to other external agents
- Lung diseases due to external agents
- Diagnoses used for exclusion with ILD
- Other pulmonary diagnosis
- Excluding asthma or asthma-COPD overlap
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 294 | 177 | 116 |
| Only index persons | 245 | 147 | 98 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.00 | 0.01 | 0.00 |
| Only index persons | 0.00 | 0.01 | 0.00 |
| Median age at first event (years) | |||
| Whole population | 70.11 | 70.84 | 68.94 |
| Only index persons | 68.88 | 69.62 | 67.77 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 67 | 45 | 22 |
| Unadjusted period prevalence (%) | 0.01 | 0.02 | 0.01 |
| Median age at first event (years) | 67.02 | 67.60 | 65.83 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
No data
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 69
- Matched controls
- 690
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
J70.4
ICD-10 Finland
Drug-induced interstitial lung disorders, unspecified
+∞
99.1
69
*
B01AB10
ATC
tinzaparin; parenteral
10.0
16.4
23
33
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
16.6
15.8
26
24
JN4AD
NOMESCO Finland
Body CT examination
8.0
14.0
24
43
J18.9
ICD-10 Finland
Pneumonia, unspecified
6.4
13.7
39
116
H02AB06
ATC
prednisolone; systemic
9.6
13.2
59
262
GD1AA
NOMESCO Finland
Thorax X-ray examination
8.4
12.7
57
250
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
7.2
12.0
22
42
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.6
9.4
23
57
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
5.9
9.4
21
48
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
10.2
9.1
18
23
H02AB02
ATC
dexamethasone; systemic
5.2
9.0
24
64
UGC12
NOMESCO Finland
Flexible bronchoscopy
8.3
8.9
20
32
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
4.9
8.7
26
76
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
38.3
8.3
10
*
A03FA01
ATC
metoclopramide; systemic, rectal
4.3
8.2
33
121
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
10.0
8.2
16
20
M04AA01
ATC
allopurinol; systemic
5.2
8.1
21
54
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
9.6
7.9
16
21
I48
ICD-10 Finland
Atrial fibrillation and flutter
4.3
7.9
29
99
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
9.1
7.7
16
22
TGC00
NOMESCO Finland
Bronchial lavation
15.8
7.7
12
9
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
13.0
7.7
13
12
JN4BD
NOMESCO Finland
Extensive body CT
5.0
7.6
20
52
WD415
NOMESCO Finland
Demanding antibody therapy of methastized malignancy
89.3
7.6
8
*
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
4.1
7.6
31
114
ZXE00
NOMESCO Finland
One hour or less
4.0
7.5
42
192
TPH07
NOMESCO Finland
Cathetrisation of artery
5.5
7.4
17
39
XX3DW
NOMESCO Finland
Time consuming IT work
4.9
7.4
20
53
R06.0
ICD-10 Finland
Dyspnoea
3.9
7.2
34
137
J01MA12
ATC
levofloxacin; systemic
4.1
7.2
27
93
D70.82
ICD-10 Finland
Drug-induced neutropenia
19.1
7.0
10
6
GA4YT
NOMESCO Finland
Puncture of pleura with ultrasound guidance
19.1
7.0
10
6
ZX070
NOMESCO Finland
Intensity modified radiotherapy
25.5
6.9
9
*
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
14.2
6.9
11
9
XW000
NOMESCO Finland
Bone marrow biopsy
14.2
6.9
11
9
A04AA02
ATC
granisetron; systemic, transdermal
8.0
6.8
15
23
N02AA05
ATC
oxycodone; systemic
3.8
6.5
27
99
C01BD01
ATC
amiodarone; systemic
11.6
6.3
11
11
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.8
6.2
25
89
ZXE10
NOMESCO Finland
More than one and less than three hours
3.5
6.2
37
171
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
31
66
7.71
15.62
2.4
2.0
—
—
—
0
0
37
95
7.24
15.48
2.5
2.0
—
—
—
0
0
30
65
7.40
14.77
2.4
1.9
—
—
—
0
0
35
91
6.78
14.28
5.3
3.4
0.81
0.80
mmol/l
0.29
35
82
23
49
6.54
11.21
5.8
3.8
1.22
1.23
mmol/l
0.20
23
43
16
15
13.48
9.39
1.6
2.0
—
—
—
0
0
60
342
6.77
9.20
21.0
10.6
4.57
4.10
e9/l
0.90
54
295
54
271
5.57
9.01
7.8
6.0
1.20
1.21
mmol/l
0.43
54
244
21
52
5.37
8.54
5.7
3.2
—
—
—
0
0
56
297
5.70
8.51
8.5
7.3
1.20
1.22
mmol/l
0.82
43
251
15
16
11.62
8.29
1.6
1.9
—
—
—
0
0
13
10
15.65
8.27
1.7
1.9
—
—
—
0
0
13
10
15.65
8.27
1.7
1.7
—
—
—
0
0
41
178
4.21
8.02
3.8
3.0
0.38
0.30
e6/l
0.15
34
132
11
6
21.39
7.89
1.8
2.2
—
—
—
0
0
46
224
4.16
7.49
4.1
3.1
—
—
—
0
0
12
10
14.20
7.41
1.6
1.9
—
—
—
0
0
10
6
19.14
6.98
1.5
1.8
—
—
—
0
0
12
13
10.89
6.60
1.6
1.9
—
—
—
0
0
6
0
+∞
6.34
1.5
0.0
—
—
—
0
0
23
81
3.76
5.78
7.3
7.4
102.78
104.54
mmol/l
1.29
23
81
10
10
11.44
5.74
1.7
1.9
—
—
—
0
0
12
17
8.29
5.73
2.1
1.2
—
—
—
0
0
14
26
6.47
5.59
3.9
9.4
23.88
26.16
mmol/l
1.14
14
26
23
88
3.42
5.03
2.6
2.3
10.97
12.11
umol/l
0.34
23
79
9
10
10.13
4.95
5.6
1.8
51.22
61.90
%
—
9
10
9
10
10.13
4.95
1.8
1.7
—
—
—
0
0
9
10
10.13
4.95
4.3
1.8
26.27
24.20
mmol/l
—
9
10
48
286
3.23
4.88
23.9
13.7
1.22
1.24
inr
0.09
24
79
16
53
3.63
4.30
4.2
3.8
5.98
5.80
kpa
0.21
16
53
11
24
5.24
3.94
3.2
2.8
—
—
—
0
0
7
8
9.56
3.87
2.3
1.0
—
—
—
0
0
13
43
3.49
3.46
2.0
1.5
1.34
1.66
%
—
8
37
13
43
3.49
3.46
5.5
9.3
0.53
0.77
%
1.19
13
43
13
43
3.49
3.46
5.5
9.3
1.55
1.48
%
0.11
13
43
13
44
3.41
3.34
3.0
2.7
4.57
4.28
kpa
0.22
13
44
13
41
3.66
3.28
5.5
9.7
93.94
94.06
%
0.02
13
41
7
11
6.93
3.27
1.0
1.9
—
—
—
0
0
7
11
6.93
3.27
1.0
1.9
—
—
—
0
0
7
13
5.85
2.95
2.1
1.7
—
—
—
0
0
7
13
5.85
2.95
2.1
1.7
—
—
—
0
0
38
239
2.31
2.91
6.2
3.6
18.29
39.94
ng/l
0.79
30
177
9
23
4.34
2.89
1.1
1.2
—
—
—
0
0
30
173
2.30
2.79
4.5
4.2
0.00
0.00
estimate
-0.00
21
54
9
24
4.15
2.78
5.3
3.4
24.33
24.17
mmol/l
—
9
24
26
143
2.31
2.68
3.4
2.9
346.62
2764.74
umol/l
0.49
21
121
7
15
5.06
2.67
5.4
4.9
—
—
—
0
0
43
292
2.25
2.66
6.2
5.0
0.00
0.00
estimate
-0.00
21
56
6
11
5.85
2.60
4.5
1.4
80.83
90.09
%
—
6
11
5
7
7.58
2.59
1.8
1.0
—
—
—
0
0
5
7
7.58
2.59
1.4
1.1
—
—
—
0
0
43
296
2.20
2.52
4.7
3.8
0.00
0.00
estimate
-0.00
21
56
10
33
3.37
2.48
1.8
1.5
—
—
—
0
0
6
12
5.36
2.45
4.5
2.5
238.33
159.17
%
—
6
12
40
273
2.11
2.34
3.3
2.5
—
—
—
0
0
6
13
4.94
2.32
1.8
1.5
—
—
—
0
0
13
55
2.68
2.28
2.2
2.7
9.45
6.14
ug/l
0.29
13
50
5
9
5.89
2.25
1.0
1.9
—
—
—
0
0
5
9
5.89
2.25
1.0
1.9
—
—
—
0
0
42
296
2.07
2.21
4.8
3.8
0.00
0.00
estimate
-0.00
21
60
42
298
2.05
2.14
2.9
2.6
—
—
—
0
0
18
96
2.18
1.93
1.6
1.3
43.85
35.11
iu/ml
—
6
36
5
12
4.40
1.85
1.2
1.3
—
—
—
0
0
10
42
2.61
1.70
1.5
1.7
—
—
—
0
0
7
25
3.00
1.70
4.1
1.5
—
—
—
0
0
58
483
2.26
1.69
47.3
18.5
14.51
15.10
%
1.06
58
475
34
240
1.82
1.62
4.4
3.9
—
—
—
0
0
8
33
2.61
1.59
1.3
1.2
—
104.46
—
0
10
5
15
3.51
1.55
1.8
2.3
—
—
—
0
0
5
15
3.51
1.55
1.0
1.1
—
—
—
0
0
18
107
1.92
1.44
3.9
2.7
0.60
1.04
e6/l
0.62
11
64
5
17
3.09
1.38
3.2
3.5
13.60
58.44
u/ml
—
5
17
5
17
3.09
1.38
4.6
1.7
0.00
0.00
g/l
—
5
17
16
93
1.94
1.36
4.2
3.0
0.67
3.25
e6/l
—
9
51
8
37
2.31
1.26
1.9
1.5
—
—
—
0
0
5
20
2.61
1.17
1.2
1.3
1.25
1.14
g/l
—
5
20
5
20
2.61
1.17
1.2
1.3
0.24
0.23
g/l
—
5
20
6
30
2.09
0.89
3.0
4.0
25.18
24.94
mmol/l
—
6
30
5
23
2.26
0.78
1.6
1.5
—
—
—
0
0
30
241
1.43
0.70
2.1
2.1
88.76
94.20
pmol/l
0.22
16
103
19
141
1.48
0.66
3.9
2.1
—
—
—
0
0
5
29
1.78
0.65
3.2
2.9
54.36
46.58
%
—
5
29
6
91
0.63
0.46
8.2
7.8
—
—
—
0
0
16
123
1.39
0.46
1.5
1.7
1702.71
1279.15
nmol/l
—
10
94
5
31
1.66
0.44
3.0
2.7
2.16
1.05
%
—
5
31
0
15
0.00
0.42
0.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.8
—
—
—
0
0
0
17
0.00
0.41
0.0
1.3
—
—
—
0
0
7
94
0.72
0.24
1.3
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
11
90
1.26
0.20
2.2
2.9
0.38
0.71
ug/l
—
6
66
10
84
1.22
0.15
1.9
1.4
—
—
—
0
0
56
550
1.10
0.05
4.7
4.9
6.04
5.92
mmol/l
0.33
50
498
55
553
0.97
0.00
4.6
4.7
4.93
4.57
mmol/l
1.06
50
501
19
194
0.97
0.00
4.8
3.6
26.02
8.17
mg/mmol
0.36
11
115
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
6
0.00
-0.00
0.0
1.0
—
146.67
—
0
6
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
116.33
—
0
6
0
7
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
1146.00
—
0
6
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
6
0.00
-0.00
0.0
2.8
—
113.00
—
0
6
Mortality – FinRegistry
↥Association
Association between endpoint DRUGADVERS_INTERSTITIAL_LUNG_DISORD_UNSPE and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| DRUGADVERS_INTERSTITIAL_LUNG_DISORD_UNSPE | 2.1 [1.45, 3.04] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.217 |
During the follow-up period (1.1.1998 — 31.12.2019), 62 out of 143 females with DRUGADVERS_INTERSTITIAL_LUNG_DISORD_UNSPE died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have DRUGADVERS_INTERSTITIAL_LUNG_DISORD_UNSPE.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.214% | No data |
| 5 | 1.23% | No data |
| 10 | 3.312% | No data |
| 15 | 5.661% | No data |
| 20 | 9.969% | No data |
Relationships between endpoints
↥Index endpoint: DRUGADVERS_INTERSTITIAL_LUNG_DISORD_UNSPE – Drug-induced interstitial lung disorders, unspecified
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data